Psychoeducational Groups for Adults With ADHD

Not Applicable

Completed

• Conditions: Attention Deficit Hyperactivity Disorder

• Registration Number: NCT03337425
• Lead Sponsor: Norwegian University of Science and Technology

Brief Summary

This pilot study aims to assess patient satisfaction and preliminary efficacy of a psychoeducational group treatment, using a randomized waitlist-controlled trial, at two different outpatient clinics in mid-Norway. All participants will receive standard treatment during the intervention period. Assessment of client satisfaction (CSQ 8), general self-efficacy (GSE-6), ADHD-related quality of life (AAQoL) symptoms of ADHD (SCL-9; ASRS), and work participation will be conducted at time of recruitment prior to randomization (T0), pre- (T1), post-treatment (T2), with a 10 week follow-up.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-11-02
• Study First Submitted QC: 2017-11-06
• Study First Posted: 2017-11-09
• Study Start: 2017-11-15
• Primary Completion: 2019-06-15
• Study Completion: 2019-06-15
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-14
• Last Update Posted: 2020-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

• confirmed ADHD diagnosis
• speaking a Scandinavian language

Exclusion Criteria

• not able or willing to give informed consent
• psychosis
• severe learning difficulties

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Change in patient satisfaction	Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)	Measured with a modified version of the Client Satisfaction Questionnaire (CSQ-8). The scale consists of 8 items measured on a scale from 1 to 4. A sum score between 8 and 32 indicate the level of satisfaction with services provided.
Change in general self-efficacy	Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)	Measured with General Self-Efficacy Scale (GSE-6), a short-form measure of self-efficacy. Self-efficacy is regarded as a protective factor in adapting to stress and chronic illness. The scale consists of 6 items, measured on a 4-point scale, with a possible range of 6-24.

Secondary Outcome Measures

Name	Time	Method
Change in ADHD-related symptoms (ASRS)	Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)	Measured with ASRS, a self-reporting scale for ADHD-related symptoms in adults. The scale consists of 18 items, based on DSM-V diagnostic criteria for ADHD. The items are measured on a 5-point scale, with a possible range of 0-72.
Change in ADHD-related symptoms (SCL-9)	Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)	Measured with 9 items from the SCL-90. SCL-9 is an ADHD-specific scale, consisting of 9 items of the original 90. SCL-9 covers the specific characteristic traits of ADHD.
Change in ADHD-related quality of life	Baseline, post-intervention (10 weeks) and after 10 weeks follow-up (20 weeks)	Measured with AAQoL - which covers ADHD-specific quality of life and function. AAQoL consists of 29 questions measuring health related quality of life among adults with ADHD.

Trial Locations

Locations (2)

Levanger Hospital, Nord-Trøndelag Hospital Trust; 🇳🇴 Levanger, N-T, Norway

Tiller DPS - St. Olavs University Hospital; 🇳🇴 Trondheim, S-T, Norway